Introduction
============

Atherosclerosis is a complex inflammatory disease of large and medium‐sized arteries, resulting from interactions between genetic and environmental factors.^[@b1]^ The mouse is the leading mammalian model organism for finding genes involved in atherosclerosis and many other complex diseases.^[@b2]^ A number of candidate genes suspected of contributing to the development of atherosclerosis have been tested through construction and analysis of gene knockout or transgenic mice.^[@b3]^ Inbred mouse strains that display phenotypic differences in atherosclerosis or related traits have been used to conduct quantitative trait locus (QTL) analysis for finding new genes and pathways that give rise to the traits. To date, \>18 mouse crosses from 12 inbred strains have been constructed to identify loci for atherosclerosis, leading to the identification of 43 QTLs for aortic plaques (<http://www.informatics.jax.org/searches/allele_form.shtml>). C3H/HeJ (C3H) and C57BL/6 (B6) are the most phenotypically divergent inbred mouse strains in terms of variation in atherosclerotic lesion sizes in the aortic root.^[@b4]^ C3H mice develop much smaller lesions than B6 mice when fed an atherogenic diet or deficient in apolipoprotein E (*Apoe*^--/--^),^[@b5].[@b6]^ In a female F~2~ cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice, we identified a major locus on chromosome (Chr) 9, named *Ath29* (initially named *Ath22*), that had a major effect on atherosclerotic lesion formation in the aortic root.^[@b7]^ This locus was subsequently replicated in 2 separate intercrosses that developed fatty streak or advanced lesions.^[@b8]^

Previous studies have shown that atherosclerosis susceptibility loci mapped from a female population are often different from those mapped from a male population even though they were derived from the same cross.^[@b9]--[@b13]^ In this study, we sought to identify QTLs for atherosclerosis in a male F~2~ cohort generated from B6.*Apoe*^--/--^ and C3H.*Apoe*^--/--^ mice. Male mice are more resistant to atherosclerosis than their female counterparts, partially due to higher HDL cholesterol levels.^[@b14]--[@b16]^ Thus, the potential genetic link of atherosclerosis with plasma lipids was also explored through the cohort.

Materials and Methods
=====================

Mice
----

B6.*Apoe*^−/−^ mice were purchased from the Jackson Laboratories, and C3H.*Apoe*^−/−^ mice were created in our laboratory. The creation of a male F~2~ population from the 2 *Apoe*^−/−^ mouse strains was done as recently reported.^[@b17]^ Briefly, B6.*Apoe*^−/−^ mice were mated with C3H.*Apoe*^−/−^ mice to generate F~1~s, which were intercrossed by brother--sister mating to generate 246 male F~2~s. Mice were weaned onto a chow diet at 3 weeks of age. At 8 weeks of age, mice were switched onto a Western diet containing 21% fat, 34.1% sucrose, 0.15% cholesterol, and 19.5% casein (TD 88137; Harlan Laboratories) and maintained on the diet for 5 weeks. Mice were fasted overnight before being killed, and blood was collected via retro‐orbital venous plexus puncture with the animals under isoflurane anesthesia. After being bled, mice were killed to allow collection of the heart and tail samples. All procedures were carried out in accordance with the National Institutes of Health guidelines and approved by the institutional Animal Care and Use Committee.

Aortic Lesion Analysis
----------------------

Atherosclerotic lesions in aortic root were measured as previously reported.^[@b7]^ Briefly, mice were killed via cervical dislocation after isoflurane anesthesia. The vasculature of the animals was perfusion‐fixed with 10% formalin through the left ventricle of the heart. The aortic root and adjacent heart were excised en bloc and embedded in optimal cutting temperature compound. Serial 10‐μm‐thick cryosections from the middle portion of the ventricle to the aortic arch were collected and mounted on slides. In the region from the appearance to the disappearance of the aortic valves, every other section was collected. In all other regions, every fifth section was collected. Sections were stained with oil red O and hematoxylin and counterstained with fast green. Atherosclerotic lesion areas were measured using an ocular lens with a square‐micrometer grid on a light microscope. The lesion areas on all sections were summed and then normalized to 44 sections for each mouse, and this number was used for statistical analysis.

Plasma Lipid Analysis
---------------------

The measurements of total cholesterol, HDL cholesterol, and triglycerides were performed as reported previously.^[@b18]^ Briefly, 6 μL of plasma samples (for total cholesterol measurements, plasma was diluted 1:5 in distilled water), lipid standards, and controls was loaded onto a 96‐well plate in duplicate and then mixed with 150 μL of cholesterol or triglyceride reagents. After an 8‐minute incubation at 37°C, the absorbance at 500 nm was read on a Molecular Devices plate reader. Non‐HDL cholesterol was calculated as the difference between total and HDL cholesterol.

Genotyping
----------

DNA was isolated from the tails of mice by using the standard phenol--chloroform extraction and ethanol precipitation method. One hundred thirty‐four microsatellite markers on all 19 autosomes and the X chromosome at an interval of approximately 11 cM were screened for all of the F~2~ progeny individually by polymerase chain reaction. Parental and F~1~ DNA was also typed as controls for each marker so as to readily identify the parental origin of alleles at the marker in F~2~s.

Statistical Analysis
--------------------

QTL analysis was performed using J/qtl for atherosclerotic lesion size and plasma lipid levels in 246 male F~2~s that were genotyped for 134 micosatellite markers across the entire genome (the data have been deposited in the Mouse Genome Informatics database), as we previously reported.^[@b7],[@b17],[@b19]^ J/qtl is a Java graphic user interface for the popular QTL data analysis software R/qtl (<http://churchill.jax.org/software/jqtl.shtml>). One thousand permutations of trait values were run to define the genomewide logarithm of odds (LOD) score thresholds for significant and suggestive linkage to each trait. Loci that exceeded the 95th percentile of the permutation distribution were defined as significant (*P*\<0.05), and those exceeding the 37th percentile were suggestive (*P*\<0.63), as recommended by the Complex Trait Consortium.^[@b20]^ Permutation tests are the standard statistical approach for obtaining threshold values that are adjusted for multiple testing.^[@b21]^ In these permutation tests, genome scans are repeatedly carried out on shuffled versions of the data to estimate an LOD threshold that is appropriate for the given data set.

ANOVA was performed to determine the statistical significance of differences in phenotypic values of F~2~ mice among different genotypes at a specific marker. The mode of inheritance for a QTL was determined based on relative trait values of F~2~ mice among 3 different genotypes at the nearest marker: if a heterozygous allele (*BC*) produced the same phenotypic effect as a homozygous allele (*BB* or *CC*), the QTL effect was called "dominant" and the allele with a larger effect was called the "high allele"; if a heterozygous allele produced a phenotypic effect somewhere between the effect of the 2 homozygous alleles (*BB* and *CC*), it was called "additive"; if an allele only expressed a phenotypic effect in the homozygous condition, it was called "recessive"; and if a heterozygous allele produced a phenotypic effect that exceeded the effect of the 2 homozygous alleles, it was called "heterosis."

Prioritization of Positional Candidate Genes
--------------------------------------------

The Sanger SNP database (<http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl>) was used to prioritize candidate genes for significant atherosclerosis QTLs that had been mapped in ≥2 crosses generated from different parental strains. Probable candidate genes were defined as those with ≥1 single nucleotide polymorphisms (SNPs) in coding or upstream promoter regions that were shared by the parental strains carrying the "high" allele but were different from the parental strains carrying the "low" allele at a QTL.

Results
=======

Trait Value Frequency Distributions
-----------------------------------

Values of atherosclerotic lesion sizes in the aortic root of 246 male F~2~ mice were distributed in a Pareto manner: the number of F~2~ mice with a lesion size of ≤10 000 μm^2^ is the largest and then decreases as lesion sizes increase ([Figure 1](#fig01){ref-type="fig"}). After being transformed using natural logs (LN), the values of atherosclerotic lesion sizes approach a normal distribution. The values of log‐transformed HDL cholesterol, non‐HDL cholesterol, and log‐transformed triglyceride concentrations in F~2~ mice are approximately normally distributed. These data were then analyzed using J/qtl software to detect significant and suggestive QTLs affecting the traits.

![Frequency distributions of atherosclerotic lesion sizes and plasma lipid levels in 246 male F~2~ mice after being fed a Western diet for 5 weeks. The F~2~ progeny was generated from an intercross between B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice. Note that the unit for untransformed atherosclerotic lesion sizes is "μm^2^×1000," whereas the unit for LN‐transformed atherosclerotic lesion sizes is "μm^2^." LN indicates natural logs.](jah3-2-e000260-g1){#fig01}

Atherosclerotic Lesions
-----------------------

We first performed a genomewide scan using untransformed atherosclerotic lesion size data to detect main‐effect loci with the nonparametric mode and found 4 significant QTLs, located on Chr2, Chr4, Chr9, and Chr15, and 2 suggestive QTLs, with 1 on distal Chr4 and 1 on Chr7 ([Figure 2](#fig02){ref-type="fig"}). Details of the QTLs found, including locus name, LOD score, peak location, 95% CI, genomewide significance *P* value, high allele, and mode of inheritance, are presented in [Table 1](#tbl01){ref-type="table"}. Unexpectedly, the C3H allele was associated with increased lesion sizes for 2 of the 4 significant QTLs, including the Chr2 and Chr15 QTLs ([Table 2](#tbl02){ref-type="table"}). The Chr2 locus peaked at 100.5 cM and had a significant LOD score of 3.59 and a genomewide *P* value of 0.041. This locus was overlapping in the CI with *Ath28*, mapped in an Akr.*Apoe*^−/−^×DBA.*Apoe*^−/−^ intercross.^[@b9]^ The Chr15 locus peaked at 37.8 cM and had a highly significant LOD score of 5.92. This QTL replicated *Ath33*, a locus identified in a B6.*Apoe*^−/−^×C3H.*Apoe*^−/−^ intercross fed a Western diet.^[@b13]^ The interval mapping plot for Chr4 revealed 2 distinct peaks, each with an LOD score exceeding the suggestive LOD score threshold of 2.05 ([Figure 3](#fig03){ref-type="fig"}). The proximal peak occurred at 31.6 cM with a significant LOD score of 3.81, and the distal peak appeared at 77.6 cM with a suggestive LOD score of 2.14. The proximal QTL was partially overlapping with *Ath8*, a suggestive locus mapped in an SM/J×NZB/BlNJ intercross,^[@b22]^ and the distal QTL replicated *Athsq1*, a locus identified in an MOLF/Ei×B6. *Ldlr*^−/−^ backcross.^[@b11]^ Both loci exhibited a dominant effect from the B6 allele on lesion formation. The Chr9 QTL had a highly significant LOD score of 5.40 and a genomewide *P* value of \<0.0001. This QTL replicated *Ath29*, originally identified in a female cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice.^[@b7]^ The suggestive QTL on Chr7 replicated *Ath31*, identified in a B6.*Apoe*^−/−^×C3H.*Apoe*^−/−^ intercross.^[@b13]^

###### 

Significant and Suggestive QTLs for Atherosclerosis and Plasma Lipid Levels in Male F~2~ Mice Derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ Mice

  Locus Name   Chr   Trait                    LOD[\*](#tf1-1){ref-type="table-fn"}   Peak, cM   95% CI[\*](#tf1-2){ref-type="table-fn"}   *P* Value[\*](#tf1-3){ref-type="table-fn"}   High Allele[\*](#tf1-4){ref-type="table-fn"}   Mode of Inheritance[\*](#tf1-5){ref-type="table-fn"}
  ------------ ----- ------------------------ -------------------------------------- ---------- ----------------------------------------- -------------------------------------------- ---------------------------------------------- ------------------------------------------------------
  *Ath28*      2     Lesion (nonparametric)   **3.59**                               100.5      90.2 to 103.8                             0.041                                        C3H                                            Recessive
  *Ath8*       4     Lesion (nonparametric)   **3.81**                               31.6       23.6 to 77.6                              0.022                                        B6                                             Dominant
  *Athsq1*     4     Lesion (nonparametric)   2.14                                   77.6       63 to 82.6                                ...                                          B6                                             Dominant
  *Ath31*      7     Lesion (nonparametric)   2.25                                   59.1       47.1 to 73.0                              0.489                                        B6                                             Dominant
  *Ath29*      9     Lesion (nonparametric)   **5.40**                               44.2       40.2 to 48.2                              0.0001                                       B6                                             Additive
  *Ath33*      15    Lesion (nonparametric)   **5.92**                               37.8       21.8 to 43.8                              0.0001                                       C3H                                            Additive
  *Ath30*      1     Lesion (parametric)      2.34                                   39.2       3.7 to 91.7                               0.385                                        B6                                             Dominant
  *Ath1*       1     Lesion (parametric)      2.10                                   78         66 to 93                                  ...                                          B6                                             Dominant
  *Ath28*      2     Lesion (parametric)      3.24                                   100.5      88.2 to 103.8                             0.054                                        C3H                                            Recessive
  *Ath8*       4     Lesion (parametric)      **3.30**                               33.6       25.6 to 82.6                              0.047                                        B6                                             Heterosis
  *Athsq1*     4     Lesion (parametric)      2.65                                   75.6       67.6 to 82.6                              ...                                          B6                                             Dominant
  *Ath31*      7     Lesion (parametric)      2.77                                   61.1       51.1 to 73.0                              0.175                                        B6                                             Dominant
  *Ath29*      9     Lesion (parametric)      **3.65**                               46.2       40.2 to 58.2                              0.019                                        B6                                             Additive
  *Ath33*      15    Lesion (parametric)      **4.33**                               25.8       15.2 to 39.8                              0.005                                        C3H                                            Additive
  *Hdlq5*      1     HDL                      **7.30**                               67.71      65.67 to 73.67                            0.0001                                       C3H                                            Additive
  *Hdlq16*     8     HDL                      2.11                                   17.7       13.7 to 45.7                              0.617                                                                                       Heterosis
  *Hdlq17*     9     HDL                      3.04                                   20.2       0 to 34                                   ...                                          C3H                                            Additive
  *Hdlq54*     9     HDL                      **3.55**                               43.91      18.24 to 48.24                            0.054                                        C3H                                            Additive
  *Hdlq18*     12    HDL                      2.81                                   12.04      10.04 to 44.04                            0.228                                        C3H                                            Heterosis
  *Lipq2*      13    HDL                      3.05                                   64.72      21.99 to 64.72                            0.145                                        C3H                                            Dominant
  *Cq1*        1     Non‐HDL                  **4.92**                               75.67      67.71 to 85.67                            0.002                                        C3H                                            Additive
  *Chol8*      4     Non‐HDL                  2.51                                   13.55      13.55 to 57.55                            0.323                                        B6                                             Additive
  *Nhdlq12*    12    Non‐HDL                  **6.59**                               54.04      30.04 to 58.04                            0.0001                                       B6                                             Dominant
  *Chldq8*     14    Non‐HDL                  2.24                                   29.37      19.37 to 35.37                            0.488                                        C3H                                            Additive
  *Nhdlq9*     15    Non‐HDL                  2.43                                   51.82      3.82 to 53.94                             0.367                                        C3H                                            Recessive
  *Nhdlq2*     X     Non‐HDL                  2.22                                   24.59      20.59 to 58.59                            0.511                                                                                       
  *Tglq1*      1     Triglyceride             **6.42**                               77.67      73.67 to 85.67                            0.0001                                       C3H                                            Additive
  *Tgq10*      2     Triglyceride             2.62                                   49.35      24.23 to 58.23                            0.305                                        C3H                                            Dominant
  *Tgq28*      16    Triglyceride             2.51                                   9.66       9.66 to 35.66                             0.355                                        B6                                             Dominant

QTL indicates quantitative trait locus; Chr, chromosome; LOD, logarithm of odds.

LOD scores were obtained from genomewide QTL analysis using J/qtl software. The significant LOD scores are highlighted in bold. The suggestive and significant LOD score thresholds were determined by 1000 permutation tests for each trait. Suggestive and significant LOD scores were 2.045 and 3.362 for atherosclerotic lesion size (nonparametric), 1.986 and 3.277 for natural log--transformed lesion sizes (parametric), 2.123 and 3.559 for HDL cholesterol, 2.087 and 3.49 for non‐HDL cholesterol, and 2.12 and 3.432 for triglycerides, respectively.

The 95% CI in cM defined by a whole genome QTL scan.

The *P* values reported represent the level of genomewide significance as they were generated by J/qtl basedon genomewide permutation tests.

High allele---the allele with a larger allelic effect at the peak marker of a QTL.

Mode of inheritance was defined according to allelic effect at the nearest marker of a QTL: dominant, a heterozygous allele produced the same phenotypic effect as a homozygous allele; additive, a heterozygous allele produced a phenotypic effect between the effect of the 2 homozygous alleles; recessive, an allele only expressed a phenotypic effect in the homozygous condition; and heterosis, a heterozygous allele produced a phenotypic effect exceeding the effect of the 2 homozygous alleles.

###### 

Effects of B6 (B) and C3H (C) Alleles in Different QTLs on Atherosclerosis and Plasma Lipids in the Intercross Between B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ Mouse Strains

  Locus Name^a^   Chr   Trait                    LOD        Peak, cM   Closest Marker   BB                     BC                      CC                     *P* Value
  --------------- ----- ------------------------ ---------- ---------- ---------------- ---------------------- ----------------------- ---------------------- -----------
  *Ath28*         2     Lesion (nonparametric)   **3.59**   100.5      D2Mit148         12 595±12 897 (n=73)   10 848±10 165 (n=99)    28 271±36 479 (n=56)   1.8E−06
  *Ath8*          4     Lesion (nonparametric)   **3.81**   31.6       D4Mit139         15 296±13 347 (n=59)   16 945±22 166 (n=104)   12 520±24 876 (n=73)   0.396
  *Athsq1*        4     Lesion (nonparametric)   2.14       77.6       D4Mit33          15 861±24 952 (n=53)   17 479±23 433 (n=118)   10 616±12 244 (n=59)   0.136
  *Ath31*         7     Lesion (nonparametric)   2.25       59.1       D7Mit330         17 873±27 165 (n=56)   16 152±20 439 (n=118)   11 153±16 419 (n=60)   0.198
  *Ath29*         9     Lesion (nonparametric)   **5.40**   44.2       D9Mit236         22 162±22 430 (n=54)   15 020±20 472 (n=120)   10 123±20 992 (n=63)   9.26E−03
  *Ath33*         15    Lesion (nonparametric)   **5.92**   37.8       D15Mit188        9386±11 194 (n=48)     14 341±23 011 (n=120)   24 495±25 337 (n=50)   1.95E−03
  *Ath30*         1     Lesion (parametric)      2.34       39.2       D1MIT161         16 369±17 243 (n=53)   16 027±22 747 (n=121)   13 748±22 869 (n=58)   0.765
  *Ath1*          1     Lesion (parametric)      2.1        78         D1Mit270         17 752±24 695 (n=64)   16 318±23 341 (n=102    11 913±14 121 (n=67)   0.261
  *Ath28*         2     Lesion (parametric)      3.24       100.5      D2Mit148         12 595±12 897 (n=74)   10 848±10 165 (n=99)    28 271±36 479 (n=56)   1.8E−06
  *Ath8*          4     Lesion (parametric)      **3.30**   33.6       D4Mit178         14 252±12 034 (n=56)   19 297±28 313 (n=107)   10 376±12 777 (n=69)   2.41E−02
  *Athsq1*        4     Lesion (parametric)      2.65       75.6       D4Mit33          15 861±24 952 (n=53)   17479±23433 (n=118)     10 616±12 244 (n=59)   0.136
  *Ath31*         7     Lesion (parametric)      2.77       61.1       D7Mit330         17 873±27 165 (n=56)   16152±20439 (n=118)     11 153±16 419 (n=60)   0.198
  *Ath29*         9     Lesion (parametric)      **3.65**   46.2       D9Mit236         22 162±22 430 (n=54)   15 020±20 472 (n=120    10 123±20 992 (n=63)   9.26E−03
  *Ath33*         15    Lesion (parametric)      **4.33**   25.8       D15Mit143        9107±10943 (n=47)      14 181±21 364 (n=127)   22 794±25 419 (n=62)   2.41E−03
  *Hdlq5*         1     HDL                      **7.30**   67.71      D1Mit425         64.8±45.3 (n=63)       107.1±61.3 (n=113)      114.1±66.7 (n=55)      2.9E−06
  *Hdlq16*        8     HDL                      2.11       17.7       D8Mit191         81.0±53.3 (n=56)       107.9±66.8 (n=134)      83.5±49.3 (n=43)       6.5E−03
  *Hdlq17*        9     HDL                      3.04       0 to 34    D9Mit297         81.1±53.8 (n=65)       95.0±62.8 (n=105)       116.2±63.8 (n=64)      4.80E−03
  *Hdlq54*        9     HDL                      **3.55**   43.91      D9Mit236         73.2±48.7 (n=55)       95.8±60.6 (n=120)       120.2±66.7 (n=61)      1.8E−04
  *Hdlq18*        12    HDL                      2.81       12.04      D12Mit84         77.7±52.5 (n=60)       112.3±65.5 (n=98)       92.8±60.6 (n=73)       2.1E−03
  *Lipq2*         13    HDL                      3.05       64.72      D13Mit151        73.1±49.1 (n=55)       101.8±60.0 (n=116)      108.4±70.2 (n=64)      3.7E−03
  *Cq1*           1     Non‐HDL                  **4.92**   75.67      D1Mit270         696.2±341.6 (n=61)     859.7±363.9 (n=101)     976.9±332.6 (n=69)     4.3E−05
  *Chol8*         4     Non‐HDL                  2.51       13.55      D4Mit192         938.6±353.6 (n=48)     873.3±361.4 (n=106)     730.4±344.9 (n=75)     3.1E−03
  *Nhdlq12*       12    Non‐HDL                  **6.59**   54.04      D12mit277        865.6±291.4 (n=49)     909.7±373.4 (n=148)     575.3±265.7 (n=38)     1.1E−06
  *Chldq8*        14    Non‐HDL                  2.24       29.37      D14MIT155        743.9±336.3 (n=68)     869.0±359.5 (n=109)     941.3±377.4 (n=54)     8.1E−03
  *Nhdlq9*        15    Non‐HDL                  2.43       51.82      D15Mit161        830.6±327.7 (n=54)     798.9±364.9 (n=123)     977.1±358.8 (n=56)     7.9E−03
  *Nhdlq2*        X     Non‐HDL                  2.22       24.59      DXMit81          804.2±366.2 (n=110)                            875.9±358.2 (n=116)    1.4E−01
  *Tglq1*         1     Triglyceride             **6.42**   77.67      D1Mit270         111.6±26.2 (n=61)      135.5±41.6 (n=102)      148.5±48.0 (n=69)      1.9E−06
  *Tgq10*         2     Triglyceride             2.62       49.35      D2Mit126         117.4±34.5 (n=57)      139.3±46.9 (n=124)      135.7±35.6 (n=53)      4.6E−03
  *Tgq28*         16    Triglyceride             2.51       9.66       D16Mit165        133.5±48.7 (n=68)      140.9±42.7 (n=97)       119.0±31.5 (n=62)      3.7E−03

Data are mean±SD. The units for these measurements are μm^2^/section for atherosclerotic lesions and mg/dL for plasma lipid levels. The number in the brackets represents the number of progeny with a specific genotype at a peak marker. ANOVA was used to determine the significance level (*P* value) of differences for a specific phenotype among progeny with different genotypes at a specific marker. The significant LOD scores were highlighted in bold. BB indicates homozygous for B6 alleles at the linked peak marker; CC, homozygous for C3H alleles; BC, heterozygous for B6 and C3H alleles at the peak marker; QTL, quantitative trait locus; Chr, chromosome; LOD, logarithm of odds.

![Genomewide QTL analysis to search for loci influencing atherosclerotic lesion sizes in male F~2~ mice. Chromosomes 1 through 20 are represented numerically on the *x axis*. The relative width of the space allotted for each chromosome reflects the number of microsatellite markers typed for that chromosome. The *y* axis represents the LOD score. Two horizontal dashed lines denote genomewide thresholds for suggestive (*P*=0.63) and significant (*P*=0.05) linkage. The top panel shows a genomewide scan for atherosclerotic lesions using the nonparametric mode, and the bottom panel shows an autosome scan for atherosclerotic lesions using the parametric mode. For the latter scan, the X chromosome was not included due to a strong biased influence from the chromosome. QTL indicates quantitative trait locus; LOD, logarithm of odds.](jah3-2-e000260-g2){#fig02}

![Interval mapping plot for atherosclerotic lesions on chromosome 4. The plot was created with the interval mapping function of Map Manager QTX, which includes a bootstrap test shown as a histogram estimating the CI of a QTL. Two straight vertical lines on the plot represent the genomewide significance thresholds for suggestive and significant linkage. The black line denotes the LOD score calculated at 1‐cM intervals. The blue line represents the effect of the B6 allele, and the red line represents the effect of the C3H allele. The histogram indicates the existence of 2 QTLs on the chromosome. The number in the bracket denotes the mapping distance from the centromere of a specific marker in cM. LOD indicates logarithm of odds; QTL, quantitative trait locus.](jah3-2-e000260-g3){#fig03}

We then localized QTLs using the LN‐transformed atherosclerotic lesion size data and identified 2 additional suggestive QTLs on Chr1 ([Figure 2](#fig02){ref-type="fig"}). The proximal QTL peaked at 39.2 cM and had a suggestive LOD score of 2.34. This locus replicated *Ath30*, identified in a B6.*Apoe*^−/−^×C3H.*Apoe*^−/−^ intercross.^[@b13]^ The distal QTL peaked at 78 cM and had a suggestive LOD score of 2.10. This locus replicated *Ath1*, initially detected in recombinant inbred strains derived from B6 and C3H mice and subsequently replicated in several crosses.^[@b13],[@b15],[@b23]--[@b24]^ Both QTLs affected lesion sizes in a dominant manner from the B6 allele ([Table 2](#tbl02){ref-type="table"}).

Plasma Lipid Levels
-------------------

Genomewide scans revealed that plasma HDL, non‐HDL cholesterol, and triglyceride levels were each controlled by multiple QTLs ([Figure 4](#fig04){ref-type="fig"}, [Table 1](#tbl01){ref-type="table"}). For HDL, 2 significant QTLs, located on Chr1 and Chr9, and 4 suggestive QTLs, located on Chr8, Chr9, Chr12, and Chr13, were identified. The significant QTL on Chr1 replicated *Hdlq5,* which had been mapped in numerous crosses.^[@b25]^ The interval mapping graph for Chr9 showed 2 distinct QTLs with each surpassing the suggestive LOD score threshold of 2.087 ([Figure 5](#fig05){ref-type="fig"}). The distal locus peaked at 43.9 cM and had a significant LOD score of 3.55. This QTL coincided precisely with the atherosclerosis susceptibility locus on Chr9. The proximal QTL on Chr9 and the suggestive QTLs on Chr8 and Chr12 corresponded to *Hdlq17, Hdlq16*, and *Hdlq18,* respectively, previously mapped in a B6×129 F~2~ population.^[@b26]^ The QTL on Chr13 was partially overlapping in the confidence interval with *Lipq2*, identified in B6.C‐H25C×BALB/cJ F~2~ mice.^[@b27]^ For non‐HDL cholesterol, 2 significant QTLs, located on Chr1 and Chr12, and 4 suggestive QTLs, on Chr4, Chr14, Chr15, and ChrX, were identified. The Chr1 QTL replicated *Cq1*, a locus identified in a number of crosses.^[@b28]^ The Chr12 QTL replicated *Nhdlq12,* previously mapped in female mice derived from an intercross between B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice.^[@b29]^ The suggestive QTLs on Chr4, Chr14, Chr15, and ChrX replicated *Chol8*,*Chldq8*,*Nhdlq9*, and *Nhdlq2*, respectively (<http://www.informatics.jax.org/phenotypes.shtml>). Plasma triglyceride levels were controlled by 1 significant QTL on Chr1 and 2 suggestive QTLs on Chr2 and Chr16, corresponding to *Tglq1*,*Tgq10*, and *Tgq28*, respectively (<http://www.informatics.jax.org/phenotypes.shtml>).

![Genomewide scans for HDL, non‐HDL cholesterol, and triglyceride levels in the F~2~ population. Chromosomes 1 through 20 are represented numerically on the *x axis*, and the *y* axis represents the LOD score. Two horizontal dashed lines denote genomewide thresholds for suggestive and significant linkage. LOD indicates logarithm of odds; HDL, high‐density lipoprotein.](jah3-2-e000260-g4){#fig04}

![LOD score plots for HDL cholesterol levels (left) and atherosclerotic lesion size (right) on chromosome 9. Plots were created with the interval mapping function of Map Manager QTX. The histogram shown in the plots indicates the confidence interval of a QTL. The distal QTL for HDL coincided with the QTL for atherosclerotic lesions on chromosome 9. The number in the bracket denotes the cM value of a specific marker. LOD indicates logarithm of odds; QTL, quantitative trait locus; HDL, high‐density lipoprotein.](jah3-2-e000260-g5){#fig05}

Relationships Between Plasma Lipids and Atherosclerosis
-------------------------------------------------------

The associations of atherosclerotic lesion sizes with plasma lipid levels were analyzed using the F~2~ population ([Figure 6](#fig06){ref-type="fig"}). A significant inverse correlation between lesion sizes and plasma HDL cholesterol levels was observed (*r*=−0.19, *P*=0.0041). LN‐transformed lesion sizes showed an improved inverse association with plasma HDL cholesterol levels (*r*=−0.327, *P*=4.07E−7). F~2~ mice with higher HDL cholesterol levels tended to develop smaller atherosclerotic lesions. No significant correlation was observed between non‐HDL cholesterol levels and lesion sizes, although there was a trend toward statistical significance between untransformed lesion sizes and non‐HDL cholesterol levels (*r*=0.12, *P*=0.063).

![Scatterplots showing relationships of atherosclerotic lesion sizes with HDL and non‐HDL cholesterol levels in the F~2~ population. Each point represents an individual value of an F~2~ mouse. The correlation coefficient (*r*) and significance (*P*) are shown. Plasma levels of HDL but not non‐HDL cholesterol were significantly correlated with the sizes of atherosclerotic lesions. Top row: untransformed atherosclerotic lesion sizes in "μm^2^×1000"; bottom row: LN‐transformed atherosclerotic lesion sizes in "μm^2^". LN indicates natural logs; HDL, high‐density lipoprotein.](jah3-2-e000260-g6){#fig06}

Prioritization of Positional Candidate Genes for Atherosclerosis QTLs
---------------------------------------------------------------------

The C3H allele was responsible for increased lesion formation for 2 of the 4 significant QTLs: *Ath28* on Chr2 and *Ath33* on Chr15. As *Ath28* has been mapped in 2 separate intercrosses, including a previously reported AKR.*Apoe*^−/−^×DBA.*Apoe*^−/−^ cross,^[@b9]^ we conducted a haplotype analysis using the Sanger SNP database to prioritize positional candidate genes for the QTL. A few candidate genes underneath the linkage peak of *Ath28* were identified, including *Rbm38* (173 Mb), *Cdh4* (179 Mb), *Ss18l1* (179.7 Mb), *Hrh3* (179.8 Mb), *Osbpl2* (179.8 Mb), and *Lama5* (179.9 Mb) ([Table 3](#tbl03){ref-type="table"}). These candidates contain ≥1 nonsynonymous SNPs in coding regions or SNPs in the upstream regulatory region that are shared by the low allele strains (B6 and AKR) but are different from the high allele strains (C3H and DBA) at the QTL. These genes were further examined for associations with relevant human diseases using a public accessible genomewide association study database (<http://www.genome.gov/GWAStudies/>). *Rbm38* has been shown to be associated with variation in the magnitude of statin‐mediated reduction in total and LDL cholesterol^[@b30]^ and *Cdh4* with sudden cardiac arrest in patients with coronary heart disease.^[@b31]^ *Lama5* was associated with colorectal cancer in European ancestry individuals.^[@b32]^

###### 

Haplotype Analysis to Prioritize Candidate Genes for Atherosclerosis QTLs on Chromosomes 2 and 15

  Gene       Chromosome   Position    Low Allele   High Allele   Consequence       
  ---------- ------------ ----------- ------------ ------------- ------------- --- -----------------------
  *Rbm38*    2            172847290   G            G             c             c   5′\_UTR
  *Rbm38*    2            172847496   G            G             A             A   5′\_UTR
  *Cdh4*     2            179177190   C            C             T             T   5′\_UTR
  *Cdh4*     2            179179412   G            G             A             A   NON_SYNONYMOUS_CODING
  *Ss18l1*   2            179777235   C            C             G             G   5′\_UTR
  *Hrh3*     2            179835661   C            C             T             T   NON_SYNONYMOUS_CODING
  *Osbpl2*   2            179854116   G            G             A             A   5′\_UTR
  *Lama5*    2            179913809   C            C             A             A   NON_SYNONYMOUS_CODING
  *Lama5*    2            179915098   T            T             G             G   NON_SYNONYMOUS_CODING
  *Lama5*    2            179920402   C            C             T             T   NON_SYNONYMOUS_CODING
  *Lama5*    2            179920521   G            G             T             T   NON_SYNONYMOUS_CODING
  *Lama5*    2            179921374   T            T             C             C   NON_SYNONYMOUS_CODING
  *Lama5*    2            179925043   C            C             T             T   NON_SYNONYMOUS_CODING
  *Lama5*    2            179928191   A            A             G             G   5′\_UTR
  *Lama5*    2            179928517   G            G             A             A   5′\_UTR
  *Lama5*    2            179929976   C            C             T             T   NON_SYNONYMOUS_CODING
  *Lama5*    2            179933048   G            G             A             A   5′\_UTR
  *Lama5*    2            179933067   G            G             T             T   NON_SYNONYMOUS_CODING
  *Lama5*    2            179933747   T            T             A             A   5′\_UTR
  *Lama5*    2            179933873   G            G             A             A   NON_SYNONYMOUS_CODING

  Gene         Chromosome   Position   B6      C3H/HeJ   129   Consequence
  ------------ ------------ ---------- ---- -- --------- ----- -----------------------
  *Rhpn1*      15           75543724   A       G         G     NON_SYNONYMOUS_CODING
  *Apol11b*    15           77468437   A       c         C     NON_SYNONYMOUS_CODING
  *Cacng2*     15           77950358   G       A         A     5′\_UTR
  *Ift27*      15           78004380   C       A         A     5′\_UTR
  *Ncf4*       15           78075365   T       C         C     5′\_UTR
  *Ncf4*       15           78081428   G       A         A     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78115054   G       t         t     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78115310   T       C         c     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78115528   C       t         t     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78115654   A       G         G     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78115727   T       C         C     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78117449   A       G         G     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78119364   T       A         A     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78122957   C       G         g     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78122983   G       a         A     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78123018   T       g         G     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78123283   G       A         A     NON_SYNONYMOUS_CODING
  *Csf2rb2*    15           78127509   C       G         G     NON_SYNONYMOUS_CODING
  *Mpst*       15           78240804   A       G         G     NON_SYNONYMOUS_CODING
  *Sstr3*      15           78370921   C       T         T     NON_SYNONYMOUS_CODING
  *Sstr3*      15           78370941   G       A         A     NON_SYNONYMOUS_CODING
  *Sstr3*      15           78371011   C       G         G     5′\_UTR
  *Sstr3*      15           78374301   G       A         A     5′\_UTR
  *Sstr3*      15           78374693   A       G         G     5′\_UTR
  *Sstr3*      15           78374764   T       C         C     5′\_UTR
  *Gm6723*     15           78384992   C       T         T     NON_SYNONYMOUS_CODING
  *Gm6723*     15           78385151   G       C         C     NON_SYNONYMOUS_CODING
  *Mfng*       15           78603821   A       G         G     5′\_UTR
  *Card10*     15           78633071   G       A         A     5′\_UTR
  *Card10*     15           78633319   T       C         C     5′\_UTR
  *Cdc42ep1*   15           78677764   G       A         A     5′\_UTR
  *Cdc42ep1*   15           78679988   T       C         C     NON_SYNONYMOUS_CODING
  *Cdc42ep1*   15           78680104   G       A         A     NON_SYNONYMOUS_CODING
  *Cdc42ep1*   15           78680263   G       A         A     NON_SYNONYMOUS_CODING
  *Lgals2*     15           78681495   T       C         C     NON_SYNONYMOUS_CODING
  *Gcat*       15           78873505   A       G         G     NON_SYNONYMOUS_CODING
  *Micall1*    15           78957630   C       T         T     NON_SYNONYMOUS_CODING
  *Pick1*      15           79060137   A       G         G     5′\_UTR
  *Pick1*      15           79079229   A       G         G     NON_SYNONYMOUS_CODING
  *Pick1*      15           79086211   A       C         C     NON_SYNONYMOUS_CODING
  *Pick1*      15           79086466   G       T         T     NON_SYNONYMOUS_CODING
  *Pick1*      15           79086508   A       g         G     NON_SYNONYMOUS_CODING
  *Pick1*      15           79086512   C       g         G     NON_SYNONYMOUS_CODING
  *Tmem184b*   15           79209126   C       A         A     5′\_UTR
  *Csnk1e*     15           79269395   A       G         G     5′\_UTR
  *Csnk1e*     15           79271799   C       T         T     5′\_UTR
  *Nptxr*      15           79624881   T       G         G     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79722929   C       A         A     5′\_UTR
  *Apobec3*    15           79725453   A       T         T     5′\_UTR
  *Apobec3*    15           79725492   T       A         A     5′\_UTR
  *Apobec3*    15           79725494   T       G         G     5′\_UTR
  *Apobec3*    15           79725534   A       G         G     5′\_UTR
  *Apobec3*    15           79725547   G       A         A     5′\_UTR
  *Apobec3*    15           79725550   T       A         A     5′\_UTR
  *Apobec3*    15           79725566   G       A         A     5′\_UTR
  *Apobec3*    15           79725868   G       A         A     5′\_UTR
  *Apobec3*    15           79725887   G       C         C     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79725897   A       T         T     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79725900   G       A         A     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79728257   A       G         G     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79728260   G       C         C     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79728323   G       A         A     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79728327   A       G         G     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79728339   C       A         A     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79728604   G       A         A     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79729463   T       C         C     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79729537   G       C         C     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79735878   A       G         G     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79735881   G       C         C     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79735885   C       T         T     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79735953   C       G         G     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79736838   C       T         T     NON_SYNONYMOUS_CODING
  *Apobec3*    15           79737380   G       A         A     NON_SYNONYMOUS_CODING
  *Cbx7*       15           79749323   C       T         T     NON_SYNONYMOUS_CODING
  *Cbx7*       15           79749453   G       C         C     NON_SYNONYMOUS_CODING
  *Cbx7*       15           79764235   T       G         G     NON_SYNONYMOUS_CODING
  *Cbx7*       15           79764259   A       T         T     STOP_GAINED
  *Cbx7*       15           79764307   A       T         T     NON_SYNONYMOUS_CODING
  *Cbx7*       15           79801396   G       T         T     5′\_UTR
  *Cbx7*       15           79801461   A       C         C     5′\_UTR
  *Pdgfb*      15           79830813   C       T         T     NON_SYNONYMOUS_CODING
  *Pdgfb*      15           79844499   T       G         G     5′\_UTR
  *Pdgfb*      15           79844550   A       C         C     5′\_UTR
  *Pdgfb*      15           79844807   G       T         T     5′\_UTR
  *Pdgfb*      15           79844895   G       A         A     5′\_UTR

Analysis was performed using the Sanger SNP database (<http://www.sanger.ac.uk/cgi-bin/modelorgs/mousegenomes/snps.pl>). QTL indicates quantitative trait locus.

*Ath33* on Chr15 has been mapped in 3 independent intercrosses, including 2 B6.*Apoe*^−/−^×C3H.*Apoe*^−/−^ intercrosses and 1 B6.*Apoe*^−/−^×129.*Apoe*^−/−^ intercross.^[@b13],[@b23]^ C3H and 129 are the high allele strains and B6 is the low allele strain for the QTL. Positional candidate genes, such as *Rhpn1* (75.5 Mb), *Apol11b* (77.4 Mb), *Csf2rb2* (78.1 Mb), *Cdc42ep1* (78.6 Mb), *Apobec3* (79.7 Mb), and *Pdgfb* (79.8 Mb), contain ≥1 nonsynonymous SNPs that are shared by the high allele strains but different from the low allele strain. *Cacng2* (77.9 Mb) and *Card10* (78.6 Mb) are positional genes possessing SNPs in the upstream promoter region that are shared by the high allele strains but different from the low allele strain. However, none of these candidate genes have been reported for associations with atherosclerotic arterial disease in recent genomewide association studies.

Discussion
==========

Male mice are more resistant to atherosclerosis than their female counterparts for almost all inbred strains examined.^[@b14],[@b33]--[@b34]^ Higher HDL cholesterol levels have been considered to be a major contributor to the resistance of male mice to atherosclerosis.^[@b14]^ In this study, we performed QTL analysis using an F~2~ cohort from the most phenotypically divergent *Apoe*^−/−^ mouse strains to explore potential genetic connections between atherosclerosis and plasma lipids. Four significant and 4 suggestive QTLs for atherosclerotic lesion sizes and 15 QTLs for plasma HDL, non‐HDL cholesterol, and triglyceride levels have been identified. Atherosclerosis susceptibility loci are distinct from those for plasma lipids except for the Chr9 locus, which exerts effects through interactions with HDL.

*Ath29* is a significant QTL for atherosclerosis initially identified by our group from a female F~2~ cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice.^[@b7]^ It is located on mouse Chr9 at 42 cM with the B6 allele contributing to increased lesion sizes. The present study replicated this QTL in a male F~2~ population and further revealed its coincidence with an HDL QTL, *Hdlq54*.^[@b32],[@b35]^ The colocalization of loci for 2 different traits suggests a possibility that these traits are controlled by a same gene. *Elovl5* (77.7 Mb), *Elovl4* (83.7 Mb), and *Me1* (86.5 Mb) are positional candidate genes involved in fatty acid synthesis or elongation, and *Cyb5r4* (86.9 Mb) is a positional candidate gene involved in fatty acid catabolism and oxidative stress.^[@b36]^ These genes are polymorphic among the parental strains (B6 versus C3H and 129) of 3 intercrosses that have led to detection of the QTL.^[@b23],[@b35]^ *Tcf12* (71.7 Mb) is also a promising candidate gene with multiple nonsynonymous SNPs between the B6 and C3H strains. It encodes the transcription factor 12 (also called HTF4 or HEB), a member of the helix‐loop‐helix protein family.^[@b37]^ The product of *Tcf12* has diverse functions, including downregulating E‐cadherin expression, enhancing cell migration and invasion,^[@b38]^ and activating T‐lymphocyte differentiation,^[@b39]^ all of which have a role in atherosclerosis.

An interesting finding of this study is the detection of atherosclerosis susceptibility QTLs on Chr2 and Chr15 in which the C3H allele contributed to increased lesion sizes. F~2~ mice homozygous for the C3H allele at the loci had larger lesion sizes than those homozygous for the B6 allele. This finding was unexpected given the extremity of resistance that C3H.*Apoe*^−/−^ mice exhibit during the development of atherosclerosis. However, this may not be surprising given the fact that QTL mapping detects loci based on the phenotypic variance among different genotypes at genetic markers within an F~2~ or N~2~ (second backcross generation) population but not on the phenotypic variance between the 2 parental strains. Both F~2~s and N~2~s are genetically and phenotypically diverse compared with both parents and thus can lead to revelations of cryptic genetic effects. Atherosclerosis susceptibility loci derived from the resistant strains of crosses have been previously detected in at least 3 independent crosses, including a B6×FVB/N Ldlr^−/−^ intercross, B6×FVB/N *Apoe*^−/−^ intercross, and a B×H *Apoe*^−/−^ intercross.^[@b10],[@b12]--[@b13]^ The Chr2 QTL replicated *Ath28*, originally identified in a DBA/2.*Apoe*^−/−^×AKR.*Apoe*^−/−^ intercross^[@b9]^ and recently mapped in a B6.*Apoe*^−/−^×129.*Apoe*^−/−^ intercross.^[@b23]^ The CI of the Chr2 QTL (90 to 104 cM) is corresponding to human Chr20q13, a region associated with sudden cardiac arrest in patients with coronary artery disease and inflammatory and autoimmunal diseases.^[@b31],[@b40]--[@b41]^ The 2 strongest candidate genes for this QTL are *Lama5* and *Cdh4*. *Lama5* encodes laminin, α5, which, together with collagen IV, nidogen/entactin, and heparan sulfate proteoglycans, constitutes the structural component of vascular basement membrane.^[@b42]^ *Cdh4* encodes cadherin 4, a calcium‐dependent transmembrane adhesion molecule. The protein products of *Lama5* and *Cdh4* have a broad range of functions, including direct cell--cell cohesion, regulation of cell migration, proliferation, survival, and cell signaling.^[@b43]--[@b44]^

The Chr15 QTL replicated *Ath33*, previously mapped in a B6.*Apoe*^−/−^×C3H.*Apoe*^−/−^ cross and a B6.*Apoe*^−/−^×129.*Apoe*^−/−^ intercross.^[@b13],[@b23]^ The CI (22 to 44 cM) of this locus corresponds to human Chr8q24 and Chr22q13, regions that are associated with carotid intima‐media thickness,^[@b45]^ sudden cardiac arrest in patients with coronary heart disease,^[@b31]^ Crohn disease,^[@b46]^ and inflammatory bowel disease.^[@b47]^ The strongest candidate gene for the Chr15 QTL is *Pdgfb*, which encodes the platelet‐derived growth factor‐β polypeptide. Blood cells, especially monocytes and platelets, are a major source of platelet‐derived growth factor‐β after being activated.^[@b48]^ The absence of *Pdgfb* in circulating cells promotes inflammatory responses and early atherosclerosis and delays fibrous cap formation in *Apoe*^−/−^ mice.^[@b49]--[@b50]^

QTLs on distal Chr1 contributed to major variations in plasma HDL, non‐HDL cholesterol, and triglyceride levels of the cross. This finding is consistent with our previous observation in a female cohort derived from an intercross between B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice.^[@b29]^ *Apoa2* is a well‐characterized QTL gene in the distal Chr1 region accounting for variations in plasma lipid levels of mice.^[@b51]^ *Soat1* is also a QTL gene in the region that has been confirmed to contribute to variations in plasma levels of lipids, especially HDL cholesterol.^[@b52]^ A significant QTL for non‐HDL cholesterol was mapped to Chr12 at 54 cM in the current cross. This QTL was partially overlapping in the CI with *Nhdlq12*, mapped in a B6.*Apoe*^−/−^×C3H.*Apoe*^−/−^ intercross.^[@b29]^ One prominent candidate gene for this QTL is *Cyp46a1*, encoding a member of the cytochrome P450 superfamily of monooxygenases that converts cholesterol to 24S‐hydroxycholesterol.^[@b53]^ The oxysterol products activate the liver X receptor NR1H2 and are subsequently metabolized to esters by sterol o‐acyltransferase 1.

A moderate but statistically significant reverse correlation was observed between plasma HDL cholesterol levels and atherosclerotic lesion sizes in this cross. This finding supports the concept that HDL is protective against atherosclerosis. However, such a correlation was not observed in female F~2~ mice derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice.^[@b7]^ The HDL cholesterol levels in the male F~2~s were ≈3× higher and exhibited larger variance compared with the female F~2~s (96.6±61.7 versus 34.0±27.4 mg/dL), which might explain why statistical associations with atherosclerosis were observed in the males but not in the females. We have also observed a significant reverse correlation between plasma HDL cholesterol levels and atherosclerotic lesion sizes in a B6.*Apoe*^−/−^×BALB/c.*Apoe*^−/−^ intercross, whose HDL levels are higher and display a large variance.^[@b54]^ No significant correlation between plasma levels of non‐HDL cholesterol and sizes of atherosclerotic lesions was observed in this cross or in previous crosses.^[@b7],[@b13],[@b29],[@b54]^ This finding suggests that in the absence of *Apoe*, other genetic factors than those involved in regulating plasma lipids play a key role in atherosclerosis. In the previous female F~2~ cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice, we only detected 2 QTLs for atherosclerosis and 5 QTLs for plasma lipid levels.^[@b7]^ In contrast, in the present male F~2~ cohort, we have identified 8 QTLs for atherosclerosis and 15 QTLs for plasma lipid levels ([Table 4](#tbl04){ref-type="table"}) despite the fact that the 2 intercrosses were derived from the same parental strains. There were several factors that could contribute to the discrepancy in the results between the 2 crosses: first, the previous female F~2~ mice were fed a Western diet for 12 weeks starting at 6 weeks of age, while the present male F~2~ mice were fed the diet for 5 weeks starting at 8 weeks of age. Thus, female F~2~ mice should have developed larger and more advanced lesions than male F~2~ mice. Genetic factors could exert effect differently on different stages of atherosclerosis. Second, as discussed earlier, the HDL cholesterol level in the male F~2~s was much higher and exhibited larger variance compared with the female F~2~s, which was conducive to the identification of QTLs for the trait. Third, the sex of the mice could exert a significant influence on genetic factors on atherosclerosis, as previously illustrated.^[@b9]--[@b10],[@b13]^ Finally, as the 2 crosses were constructed in different time, environmental factors could influence the results.

###### 

QTLs for Atherosclerosis and Plasma Lipids Identified in the Present Male Versus the Previously Reported Female F~2~ Cohort Derived From B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ Mice

  Locus Name   Chr   Trait          LOD (Male)   LOD (Female)
  ------------ ----- -------------- ------------ --------------
  *Ath30*      1     Lesion         2.34         ...
  *Ath1*       1     Lesion         2.10         ...
  *Ath28*      2     Lesion         **3.59**     ...
  *Ath8*       4     Lesion         **3.30**     ...
  *Athsq1*     4     Lesion         2.65         ...
  *Ath31*      7     Lesion         2.77         ...
  *Ath29*      9     Lesion         **3.65**     **4.1**
  *Ath19*      11    Lesion         ...          2.4
  *Ath33*      15    Lesion         **4.33**     ...
  *Hdlq5*      1     HDL            **7.30**     3.0
  *Hdlq21*     3     HDL            ...          2.3
  *Hdlq16*     8     HDL            2.11         ...
  *Hdlq17*     9     HDL            3.04         ...
  *Hdlq54*     9     HDL            **3.55**     ...
  *Hdlq18*     12    HDL            2.81         ...
  *Lipq2*      13    HDL            3.05         ...
  *Cq1*        1     Non‐HDL        **4.92**     **6.3**
  *Chol8*      4     Non‐HDL        2.51         ...
  *Chldq3*     5     Non‐HDL        ...          2.2
  *Nhdlq11*    9     Non‐HDL        ...          2.5
  *Nhdlq12*    12    Non‐HDL        **6.59**     ...
  *Chldq8*     14    Non‐HDL        2.24         ...
  *Nhdlq9*     15    Non‐HDL        2.43         ...
  *Nhdlq2*     X     Non‐HDL        2.22         ...
  *Tglq1*      1     Triglyceride   **6.42**     **3.8**
  *Tgq10*      2     Triglyceride   2.62         ...
  *Trigg2*     8     Triglyceride   ...          3.2
  *Tgq28*      16    Triglyceride   2.51         ...

QTL indicates quantitative trait locus; Chr, chromosome; LOD, logarithm of odds; male: the present male F~2~ cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice; female: the female F~2~ cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^−/−^ mice previously reported by our group.^7^ The significant LOD scores were highlighted in bold.

In summary, we have identified a number of QTLs affecting atherosclerosis and plasma lipid levels using a male F~2~ cohort derived from B6.*Apoe*^−/−^ and C3H.*Apoe*^--/--^ mice. Atherosclerosis susceptibility loci are independent of those for plasma lipids except for the Chr9 QTL, which appears to exert effects through interactions with HDL. Through haplotype analysis, we have narrowed the list of candidate genes for major atherosclerosis susceptibility loci.
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